Roche reported Phase 2 results for its dual GLP‑1/GIP agonist CT‑388 showing roughly 22.5% placebo‑adjusted weight loss at 48 weeks, and announced plans to advance the candidate into Phase 3 by the end of March. The mid‑stage readout positions Roche behind market leaders but competitive on percent weight loss versus peers. The company acquired the asset via Carmot Therapeutics and noted plans for broader development including combination strategies. Analysts flagged that CT‑388 must demonstrate durable safety, discontinuation rates, and commercial relevance against established agents from Novo Nordisk and Eli Lilly. GLP‑1/GIP agents stimulate incretin pathways to reduce weight; differentiation will likely depend on tolerability, retention, and real‑world discontinuation.